Secukinumab
Novartis’ Cosentyx shows benefits in Phase III AS trials
January 4, 2016Research and Development, Sales and Marketing Cosentyx, Novartis, Secukinumab, ankylosing spondylitis
Novartis says results from two Phase III studies for Cosentyx in ankylosing spondylitis (AS) showing significant clinical improvements versus placebo.Results …
Novartis psoriasis drug shows three-year efficacy
October 12, 2015Cosentyx, EADV, Novartis, Secukinumab, psoriasis
Novartis has announced new trial data confirming the efficacy of Cosentyx in patients with moderate-to-severe plaque psoriasis. The results of …
Novartis’s secukinumab meets Phase 3 goals
October 1, 2015Research and Development Novartis, Secukinumab, arthritis
Novartis has announced that its secukinumab medication for treatment of psoriatic arthritis (PsA), met its primary endpoint in the pivotal …
Novartis spends $200m on pain firm Spinifex
June 29, 2015Sales and Marketing Cosentyx, EMA401, Novartis, Secukinumab, spinifex
Novartis is spending $200 million to increase its presence in pain management through the purchase of US-Australian biotech Spinifex Pharmaceuticals. …
NICE green-light for Novartis skin drug
May 29, 2015Sales and Marketing Cosentyx, IL-17, NICE, Novartis, Secukinumab
NICE has released positive draft guidance for three treatments, including the first in a new generation of psoriasis drugs. Novartis’ …
Novartis and Abbott start year with strong Q1 sales
April 23, 2015Sales and Marketing Abbott, Amgen, Cosentyx, GSK, Neupogen, Novartis, Secukinumab, Zarxio, biosimilar, filgrastim, financials
Novartis and Abbott have both posted strong first-quarter results and made bullish predictions about their financial performance in 2015. Novartis …
Novartis gets FDA approval for psoriasis drug
January 22, 2015Sales and Marketing Cosentyx, European Commission, FDA, Novartis, Secukinumab, psoriasis
The US Food and Drug Administration (FDA) has shown Novartis’ skin condition drug Cosentyx the green light to treat patients …
Novartis to present inflammatory data
November 10, 2014Business Services AS, Novartis, PSA, Secukinumab, acr
Novartis is to present data from four pivotal Phase III trials in two debilitating inflammatory diseases at the American College …
